Practical management of patients with chronic myeloid leukemia receiving imatinib.
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementTyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementOptimizing combination therapies with existing and future CML drugsChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Chronic myeloid leukemia data from IndiaThe treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad.Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.Practical management of patients with chronic myeloid leukemia.Periorbital edema secondary to imatinib mesylate.Molecular basis and management of gastrointestinal stromal tumorsPrincipal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Chronic myelogenous leukemia: treatment and monitoring.Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia.A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancerRecurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsMeasuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation.How I treat childhood CML.Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsPTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancerMonitoring imatinib plasma concentrations in chronic myeloid leukemiaImatinib-induced fatal acute liver failureA multidisciplinary approach for the treatment of GIST liver metastasisTherapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Comprehensive Characterization of Molecular Differences in Cancer between Male and Female PatientsAdherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.Imatinib mesylate for the treatment of chronic myeloid leukemia.Imatinib use in pregnancyDasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
P2860
Q24607114-DF4DD935-4B29-40D1-BA03-34FE7C37E6D3Q26749324-3E560722-122A-4637-A9A5-F1E81E091DC5Q26830695-9F2B707F-B902-4EE0-9E1C-762658C84D0EQ28075963-D6C9C10C-84F9-43D4-ADE1-7C47ECDBE88EQ28475255-E7D985E7-C6EC-41B5-81A2-97FCF4FDC471Q30318822-7AE51953-9319-45AC-A87A-A74B29DF381CQ30754820-781E4742-7152-43A0-B404-DA0CE52BA73CQ30754830-30AC6424-46AC-4CC1-9570-C0BFEF7C8F33Q33304051-C511D4EC-DAE7-4432-BE10-19840BAC0F3DQ33398485-5EB4DCAC-8417-4D68-BA07-5DCD1882C00BQ33401360-92F8CDF7-4B1E-45F6-B4D5-F0F40CAB8E32Q33412429-93FE71EE-727D-4769-BCCB-11A3663006A1Q33662660-5512C122-C90E-400B-9BA9-AB03B1AEFE17Q33849146-7CC48324-A5FE-454D-992A-C74F07BDA958Q33867897-2FC1CEA5-4A21-449E-909F-DC705971A23BQ33903598-831F3E69-5FEE-4B9F-A78D-E6B1671F8AEDQ34443523-8F9CB34D-F83B-49D0-9218-512D48EDCED7Q34617628-9D77DF59-7EB5-4AF9-BC43-BB2BE0E98951Q34666762-4E1E90E2-8820-4A40-A563-B94686AEB02EQ34683885-C00860E4-6AE3-407F-94FA-260109E136CBQ34710706-E9D9C342-1826-4079-8DAC-07DC7BFAB261Q34763374-50DC4BDC-291A-465E-B30D-9BFB64ECFC7DQ34852517-58281EF9-EE9E-4E73-8EC9-83AA8904466DQ35008618-A1CD98E9-D368-4EA9-8E58-4CCABD2D791AQ35146312-E6DCBD3F-30E6-41E0-9675-C1C820E8E866Q35743878-9E93138D-2177-47F1-9E17-845C906721E0Q35782641-3A5992BE-344C-48F8-B6D3-F4A89F7C6332Q35802202-94340899-ED80-4A87-94F9-08BA8F65601CQ35876347-AE1C98A1-0280-40F1-83D7-F2E7A4EF452BQ35902738-67731326-1808-4600-BFBF-11A572B254D1Q35952035-937AB356-04C5-4B32-AC49-408C034DE2C0Q36153597-BA48EE9A-E435-4023-A5A8-E3ACF27EC94AQ36178243-D5E22D0F-F843-4BFD-A1F0-37096BEF8061Q36699413-1E81E5C8-FD89-4DD5-9A10-0EC8B8AEDBF9Q36822880-107B678D-A5BC-480B-9142-0FD2355DAA9BQ36895507-2FFAFFDE-D666-4DB5-A53D-43C2A2FD7547Q37057014-509D7D77-7924-418B-9AAC-92DC3A0631C5Q37183434-64D092DC-70B7-44F6-8B0E-03BDCD029DDFQ37193846-5D2EBCF3-5530-4353-BF6A-88064456DE2CQ37254728-50168EA1-E8BB-4E15-8732-69289DD02D7B
P2860
Practical management of patients with chronic myeloid leukemia receiving imatinib.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@ast
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@en
type
label
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@ast
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@en
prefLabel
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@ast
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@en
P2093
P356
P1476
Practical management of patients with chronic myeloid leukemia receiving imatinib.
@en
P2093
John M Ford
Michael W N Deininger
Stephen G O'Brien
P304
P356
10.1200/JCO.2003.11.143
P407
P577
2003-03-13T00:00:00Z